m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03807)
Name
OTSA-101-DTPA-90Y
Status
Phase 1
TTD Drug ID
D1ZG5E
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Frizzled-10 (FZD10)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Frizzled-10 (FZD10) is a therapeutic target for OTSA-101-DTPA-90Y. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of OTSA-101-DTPA-90Y through regulating the expression of Frizzled-10 (FZD10). [1], [2]
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Frizzled-10 (FZD10) is a therapeutic target for OTSA-101-DTPA-90Y. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of OTSA-101-DTPA-90Y through regulating the expression of Frizzled-10 (FZD10). [1], [2]
References
Ref 1 N(6)-Methylation of Adenosine of FZD10 mRNA Contributes to PARP Inhibitor Resistance. Cancer Res. 2019 Jun 1;79(11):2812-2820. doi: 10.1158/0008-5472.CAN-18-3592. Epub 2019 Apr 9.
Ref 2 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics. 2005 Aug;86(2):127-41. doi: 10.1016/j.ygeno.2005.04.008.